Table 3. Serum concentrations of inflammatory markers in dogs with myxomatous mitral valve disease submitted to dietary supplementation with omega-3 for 9 months.
| Variables | Times | Treatments | p* | p** | |||
|---|---|---|---|---|---|---|---|
| n | Control | n | Omega-3 | ||||
| IL-1β (ng/mL) | T0 | 13 | 26.75 ± 23.44 | 16 | 63.05 ± 77.22 | 0.143 | 0.028 |
| T3 | 10 | 31.66 ± 26.76 | 10 | 48.68 ± 38.25 | 0.105 | ||
| T9 | 9 | 81.96 ± 68.51 | 8 | 105.88 ± 52.23 | 0.328 | ||
| p*** | 0.013 | 0.110 | |||||
| IL-6 (pg/mL) | T0 | 13 | 9.19 ± 7.89 | 16 | 23.30 ± 54.47 | 0.631 | 0.402 |
| T3 | 10 | 9.56 ± 11.22 | 10 | 46.98 ± 126.20 | 0.684 | ||
| T9 | 9 | 297.01 ± 816.51 | 8 | 6.23 ± 2.22 | 0.529 | ||
| p*** | 0.927 | 0.726 | |||||
| TNF-α (pg/mL) | T0 | 13 | 9.38 ± 6.68 | 16 | 30.99 ± 77.06 | 0.579 | 0.410 |
| T3 | 10 | 10.09 ± 9.49 | 10 | 51.65 ± 142.49 | 0.684 | ||
| T9 | 9 | 196.23± 506.29 | 8 | 5.13 ± 1.09 | 0.776 | ||
| p*** | 0.872 | 0.940 | |||||
| PCR (ng/mL) | T0 | 13 | 36.78 ± 11.72 | 16 | 28.70 ± 9.21 | 0.075 | 0.311 |
| T3 | 10 | 28.24 ± 15.32 | 10 | 40.00 ± 22.93 | 0.353 | ||
| T9 | 9 | 42.65 ± 16.85 | 8 | 35.83 ± 20.94 | 0.181 | ||
| p*** | 0.105 | 0.701 | |||||
p*: Difference between treatments; p**: Difference between times; p***: Difference in treatment by time interaction; Kruskal-Wallis test at 5% of significance.